Tech Company Inital Public Offerings
Pliant Therapeutics IPO
On 6/2/2020, Pliant Therapeutics went public.
Transaction Overview
Company Name
Announced On
6/2/2020
Transaction Type
IPO
Amount
$154,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering and the Concurrent Private Placement to fund the clinical development of our lead product candidate, PLN-74809, the preclinical development of our programs in oncology and muscular dystrophy, and the remainder, if any, for additional early-stage research and development activities, for business development activities, working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
260 Littlefield Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Pliant Therapeutics (Nasdaq: PLRX) is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard Coulie
Chief Financial Officer
Keith Cummings
Chief Medical Officer
Eric Lefebvre
Vice President
Katerina Leftheris
Vice President
Scott Turner
VP - Bus. Development
Hans Hull
VP - Bus. Development
Eve-Irene Lepist
VP - Human Resources
Barbara Howes
VP - Operations
Marzena Jurek
Browse more venture capital transactions:
Prev: 6/2/2020: Ezra venture capital transaction
Next: 6/2/2020: Spiderwort venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs